Eurostars Granted Project
16th May 2018 - Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded,through a highly-competitive selection process,the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” –MODIFY-NK.
The consortium composed of Glycostem Therapeutics BV (The Netherlands), YUMAB GmbH (Germany), Explicyte(France) and OZ Biosciences SAS (France) will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a patient independent donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project.
The total reward amounts to €3,626,860.00 for the 3-year programme.
“We are proud and delighted that our innovative proposal was selected and rewarded by Eurostars funding. The synergistic combination of our consortium technologies will definitely provide a breakthrough in this exhilarating field of immunotherapy. We look forward to a fruitful collaboration and successful outcome” said Olivier Zelphati, CEO of OZ BiosciencesSas.
“This highly exciting opportunity to work in synchronisation withother healthcare companies in France and Germany, generating new cellular immunotherapy productsis very motivating. With theother consortium members we have a very good chance of learning much more about designingnewlife-saving drugs for hard-to-treat cancer patients.“added Troels Jordansen, CEO of GlycostemTherapeutics BV.
“This outstanding European research consortium aimsto develop a newtargeted,adoptive cellular immunotherapy for the treatment of hard-to-treat solid tumours without the prior need of theexpensiveand complicated processinvolvingthe isolation, modificationand expansion of patient’s own immune cells. It can be a real game changer.“ said Thomas Schirrmann, CEO ofYumabGmbH.
“Combining the key expertiseof the consortium members will bring innovative insights in the active field of immuno-oncology research. We are looking forward to initiating this strategic project taking advantage of motivating technical challenges to reach attractive therapeutic outcomes”said Alban Bessede, CEO of Explicyte.